Download PDF
Drug Res (Stuttg) 2015; 65(08): 393-397
DOI: 10.1055/s-0034-1374615
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats

H. Sharifi
1   Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Science,Urmia, Iran
,
A. M. Nayebi
2   Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3   Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
,
S. Farajnia
2   Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
,
R. Haddadi
3   Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 03 January 2014

accepted 03 April 2014

Publication Date:
29 April 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction:

Neuro-inflammation in Parkinson’s disease (PD) is associated with glial cell activation and production of different inflammatory cytokines. In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats.

Methods:

6-OHDA (8 μg/2 μl/rat) was injected unilaterally into the central region of the substantia nigra pars copmacta (SNc) and after 21 days lesioned rats were treated with buspirone and fluoxetine intraperitonealy (i.p.) for 10 days. CSF samples were collected at tenth day of drugs administration and were analysed by ELISA method to measure TNF-α, IL-1β and IL-6 levels.

Results:

The results showed that the CSF levels of TNF-α was increased 3 weeks after 6-OHDA injection while there was a significant decrease in TNF-α levels of parkinsonian animals treated with buspirone (1 mg/kg) and fluoxetine (1 mg/kg). IL-1β and IL-6 both were decreased in parkinsonian rats, while their level was increased in buspirone (1 mg/kg) and fluoxetine (1 mg/kg) treated parkinsonian rats.

Conclusion:

Our study indicates that chronic administration of buspirone and fluoxetine in 6-OHDA-lesioned rats restores central concentration of inflammatory cytokines to the basal levels. We suggest that serotonergic agents can be used as adjuvant therapy along with commonly used anti-parkinsonian drugs by modulation of cerebral inflammatory cytokines. We suggest that the further clinical investigations may be carried out to prove this hypothesis.

Key words

fluoxetine - buspirone - cytokines - 6-hydroxydopamine
 

  • References

  • 1 Matsubara K, Shimizu K, Suno M et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 2006; 1112: 126-133
    CrossrefPubMedGoogle Scholar
  • 2 Hattori N, Sato S. Animal models of Parkinson’s disease: Similarities and differences between the disease and models. Neuropathology 2007; 27: 479-483
    CrossrefPubMedGoogle Scholar
  • 3 Litteljohn D, Mangano E, Clarke M et al. Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson’s Disease. Parkinson’s Dis 2011; 2011 Article ID 713517, 18 pages
    PubMedGoogle Scholar
  • 4 Farooqui T, Farooqui AA. Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson’s Disease. Parkinson’s Dis 2011; 2011 Article ID 247467, 9 pages
    PubMedGoogle Scholar
  • 5 Schiess M. Nonsteroidal anti-inflammatory drugs protect against Parkinson neuro-degeneration: can an NSAID a day keep Parkinson disease away. Arch Neurol 2003; 60: 1043-1044
    CrossrefPubMedGoogle Scholar
  • 6 Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection?. Lancet Neurol 2009; 8: 382-397
    CrossrefPubMedGoogle Scholar
  • 7 Sawada H, Hishida R, Hirata Y et al. Activated Microglia Affect the Nigro-Striatal Dopamine Neurons Differently in Neonatal and Aged Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. J Neurosci Res 2007; 85: 1752-1761
    CrossrefPubMedGoogle Scholar
  • 8 Tansey MG, Frank-Cannon TG, McCoy Mk et al. Neuroinflammation in Parkinson’s disease: is there sufficient evidence for mechanism-based interventional therapy?. Front Biosci 2008; 1: 709-717
    PubMedGoogle Scholar
  • 9 Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines. Cur Pharm Des 2005; 11: 999-1016
    CrossrefPubMedGoogle Scholar
  • 10 Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm 2006; Suppl 70: 373-381
    PubMedGoogle Scholar
  • 11 Cenci MA, Lundblad M. Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381-392
    CrossrefPubMedGoogle Scholar
  • 12 Maeda T, Kannari K, Huo S et al. Increase of the striatal serotonergic fibers after nigrostriatal dopaminergic denervation in adult rats. International Congress Series 2003; 1251: 211-215
    CrossrefPubMedGoogle Scholar
  • 13 Bezard E, Gerlach I, Moratalla R et al. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson’s disease. Neurobiol Dis 2006; 23: 77-86
    CrossrefPubMedGoogle Scholar
  • 14 Di Matteo V, Pierucci M, Esposito E et al. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders. Prog Brain Res 2008; 172: 423-463
    PubMedGoogle Scholar
  • 15 Nayebi AM, Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors. Daru 2010; 18: 41-45
    PubMedGoogle Scholar
  • 16 Mignon L, Wolf WA. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson’s disease. J Psychopharmacol 2007; 192: 49-59
    CrossrefPubMedGoogle Scholar
  • 17 Mahmoudi J, Nayebi AM, Samini M et al. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharmacol Reports 2011; 63: 908-914
    PubMedGoogle Scholar
  • 18 Rylander D, Parent M, O-Sullivan SS et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010; 68: 619-628
    CrossrefPubMedGoogle Scholar
  • 19 Lane EL, Cheetham S, Jenner P. Dopamine Uptake Inhibitor-Induced Rotation in 6-Hydroxydopamine-Lesioned Rats Involves Both D1 and D2 Receptors but Is Modulated through 5-Hydroxytryptamine and Noradrenaline Receptors. J Pharmacol Exp Ther 2005; 312: 1124-1131
    PubMedGoogle Scholar
  • 20 Madhavan L, Freed WJ, Anantharam V et al. 5-Hydroxytryptamine 1A Receptor Activation Protects against N-Methyl-D-aspartate-Induced Apoptotic Cell Death in Striatal and Mesencephalic Cultures. J Pharmacol Exp Ther 2003; 304: 913-923
    PubMedGoogle Scholar
  • 21 Adayev T, El-Sherif Y, Barua M et al. Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem 1999; 72: 1489-1496
    PubMedGoogle Scholar
  • 22 Nayebi AM, Reyhani Rad S, Saberian M et al. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rat. Pharmacol Reports 2010; 62: 258-264
    PubMedGoogle Scholar
  • 23 Mahmoudi J, Nayebi AM, Reyhani-Rad S et al. Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine Induced Motor Impairments in Rats. Advanced Pharmaceutical Bulletin 2012; 2: 149-155
    PubMedGoogle Scholar
  • 24 Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008; 85: 1-74
    CrossrefPubMedGoogle Scholar
  • 25 Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press; Sydney: 1982
    CrossrefGoogle Scholar
  • 26 Sharifi H, Nayebi AM, Farajnia S. 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats. Iran J Basic Med Sci 2013; 16: 1270-1275
    PubMedGoogle Scholar
  • 27 Sharifi H, Nayebi AM, Farajnia S. Dose-Dependent Effect of Fluoxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors. Advanced Pharmaceutical Bulletin 2013; 3: 203-206
    PubMedGoogle Scholar
  • 28 Sharifi H, Nayebi AM, Farajnia S. The Effect of Chronic Administration of Buspirone on 6-Hydroxydopamine-Induced Catalepsy in Rats. Advanced Pharmaceutical Bulletin 2012; 2: 127-131
    PubMedGoogle Scholar
  • 29 Teismann P, Schulz JB. Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation. Cell Tissue Res 2004; 318: 149-161
    CrossrefPubMedGoogle Scholar
  • 30 McCoy MK, Ruhn KA, Martinez TN et al. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 2008; 16: 1572-1579
    CrossrefPubMedGoogle Scholar
  • 31 Członkowska A, Jastrzębska IK. Inflammation and gliosis in neurological diseases – clinical implications. J Neuroimmunol 2011; 231: 78-85
    CrossrefPubMedGoogle Scholar
  • 32 Schintu N, Frau L, Ibba M et al. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson’s disease. Neurotox Res 2009; 16: 127-139
    CrossrefPubMedGoogle Scholar
  • 33 Blandini F, Armentero MT, Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008; 14: S124-S129
    CrossrefPubMedGoogle Scholar
  • 34 Lofrumento DD, Saponaro C, Cianciulli A et al. MPTP induced neuroinflammation increases the expression of proinflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2010; 18: 79-88
    PubMedGoogle Scholar
  • 35 Luchtman DW, Shao DI, Song C. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson’s disease. Physiol Behav 2009; 98: 130-138
    CrossrefPubMedGoogle Scholar
  • 36 Duke DC, Moran LB, Pearce RK et al. The medial and lateral substantia nigra in Parkinson’s disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 2007; 8: 83-94
    CrossrefPubMedGoogle Scholar
  • 37 McCoy MK, Martinez TN, Ruhn KA et al. Blocking soluble tumor necrosis factor signaling with dominant-negative TNF inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 2006; 26: 9365-9375
    CrossrefPubMedGoogle Scholar
  • 38 Shaftel SS, Griffin WST, O’Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008; 5: 7 DOI: 10.1186/1742-2094-5-7.
    CrossrefPubMedGoogle Scholar
  • 39 Knobelman DA, Kung HF, Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J Pharmacol Exp Ther 2000; 292: 1111-1117
    PubMedGoogle Scholar
  • 40 Dupre KB, Eskow KL, Barnum CJ et al. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55: 1321-1328
    CrossrefPubMedGoogle Scholar
  • 41 Bezard E, Gerlach I, Moratalla R et al. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson’s disease. Neurobiol Dis 2006; 23: 77-86
    CrossrefPubMedGoogle Scholar
  • 42 John R, Mukhin YV, Gelasco A et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001; 92: 179-212
    CrossrefPubMedGoogle Scholar
  • 43 Charkhpour M, Nayebi AM, Doustar Y et al. 8-OH-DPAT Prevents Morphine-Induced Apoptosis in Rat Dorsal Raphe Nucleus: A Possible Mechanism for Attenuating Morphine Tolerance. Anesth Analg 2010; 111: 1316-1321
    CrossrefPubMedGoogle Scholar
  • 44 Qin L, Wu X, Block ML et al. Systemic LPS Causes Chronic Neuroinflammation and Progressive Neurodegeneration. Glia 2007; 55: 453-462
    CrossrefPubMedGoogle Scholar
  • 45 Shadrina MI, Slominsky PA, Limborska SA. Molecular Mechanisms of Pathogenesis of Parkinson’s Disease. Int Rev Cell Mol Biol 2010; 281: 229-266
    PubMedGoogle Scholar
  • 46 Nagatsu T. Parkinson’s disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 2009; 109: 731-745
    PubMedGoogle Scholar
  • 47 Imamura K, Hishikawa N, Suzuki KOH et al. Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol 2005; 109: 141-150
    CrossrefPubMedGoogle Scholar
  • 48 Bick RJ, Poindexter BJ, Kott MM et al. Cytokines disrupt intracellular patterns of Parkinson’s disease-associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Brain Res 2008; 1217: 203-212
    CrossrefPubMedGoogle Scholar